Here are the DEF 14A proxy statements from ImageneBio, Inc. (IMA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow IMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMA filings page.
ImageneBio, Inc. is holding a virtual 2026 Annual Meeting on June 16, 2026, for stockholders of record as of April 28, 2026. Stockholders will vote on electing two Class II directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving an amended 2025 Equity Incentive Plan.
The equity plan amendment would add 850,000 shares to the plan and revise its evergreen formula to factor in shares issuable upon conversion of preferred stock and cash exercise of prefunded warrants. As of April 28, 2026, 11,279,130 shares of common stock were outstanding, and equity awards included 1,187,218 options and 652,517 restricted stock units.
The proxy describes ImageneBio’s post‑merger governance structure, with a classified board, a non‑executive chair, a lead independent director, fully independent key committees, and policies covering risk oversight, insider trading, hedging, and director independence. It also details audit fees and confirms prior auditor transition from Ernst & Young LLP to PricewaterhouseCoopers LLP.